Bristol Myers Squibb (CELG-RI) Prepaid Assets (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Prepaid Assets of $4.2 billion for Q2 2026, down 22.76% year-over-year from $5.5 billion in Q2 2025, and down 8.16% quarter-over-quarter from $4.6 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Prepaid Assets (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Prepaid Assets for 18 consecutive years, with $4.2 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Prepaid Assets fell 22.76% year-over-year to $4.2 billion; the TTM figure through Jun 2026 stood at $4.2 billion (down 22.76% YoY), while the FY2025 annual figure was $4.6 billion, down 17.87% from the prior year.
- Prepaid Assets declined to $4.2 billion in Q2 2026 per CELG-RI's latest filing, from $4.6 billion in the prior quarter.
- Across five years, Prepaid Assets topped out at $7.2 billion in Q3 2023 and bottomed at $4.2 billion in Q2 2026.
- Historically, Prepaid Assets has averaged $5.5 billion across 5 years, with a median of $5.6 billion in 2024.
- Annual changes were most pronounced in 2022 — Prepaid Assets soared 39.11% — and 2026, when it decreased 22.76%.
- Bristol Myers Squibb's Prepaid Assets stood at $5.8 billion in 2022, then rose by 1.93% to $5.9 billion in 2023, then decreased by 4.91% to $5.6 billion in 2024, then dropped by 17.87% to $4.6 billion in 2025, then retreated by 8.48% to $4.2 billion in 2026.
- Business Quant data shows CELG-RI's Prepaid Assets at $4.2 billion in Q2 2026, $4.6 billion in Q1 2026, and $4.6 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.22 Bn |
| Mar 31, 2026 | 4.60 Bn |
| Dec 31, 2025 | 4.61 Bn |
| Sep 30, 2025 | 4.95 Bn |
| Jun 30, 2025 | 5.47 Bn |
| Mar 31, 2025 | 5.53 Bn |
| Dec 31, 2024 | 5.62 Bn |
| Sep 30, 2024 | 5.62 Bn |
| Jun 30, 2024 | 5.74 Bn |
| Mar 31, 2024 | 5.57 Bn |
| Dec 31, 2023 | 5.91 Bn |
| Sep 30, 2023 | 7.21 Bn |
| Jun 30, 2023 | 6.87 Bn |
| Mar 31, 2023 | 5.16 Bn |
| Dec 31, 2022 | 5.80 Bn |
| Sep 30, 2022 | 6.08 Bn |
| Jun 30, 2022 | 5.76 Bn |
| Mar 31, 2022 | 4.54 Bn |
| Dec 31, 2021 | 4.83 Bn |
| Sep 30, 2021 | 4.37 Bn |